BioVantra, LLC, an innovative anatomic pathology and molecular diagnostics company, is positioned to become a leader in the translation, development, and delivery of genomic tests that are specifically designed to provide physicians and patients with information to better manage cancer and other chronic diseases. Using advanced technology, BioVantra identifies and validates small-to-medium sets of genomic markers that are used to make practical, meaningful and easy-to-use diagnostic, prognostic and targeted therapy tests for clinicians, researchers and pharmaceutical development.

We understand the importance of accurate, timely diagnostic test results and actionable healthcare information; our commitment to these values helps ensure superior patient care and increased client satisfaction.